As alcohol-related deaths climb, new drugs could curb the urge to drink

A drug developed by Kinnov Therapeutics halved alcohol consumption in heavy drinkers in a mid-stage study.

By Kelly Bilodeau • Nov. 27, 2023

Organon’s chief medical officer wants to change how the world sees women’s health

Dr. Juan Camilo Arjona Ferreira joined Organon in September and says the company is “like a lighthouse in women’s health” in its visibility and focus.

By Michael Gibney • Nov. 22, 2023

Explore the Trendline➔

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

By PharmaVoice staff

The biopharma COO’s playbook

Connie Chang, COO at ONL Therapeutics, describes what it takes to bring a CEO’s vision to life.

By Alexandra Pecci • Nov. 21, 2023

Biohaven wants to muscle in on the Ozempic craze with a competing class of drugs

Biohaven and other companies are aiming to develop meds with a different mechanism of action that trim the waistline while building lean tissue.

By Kelly Bilodeau • Nov. 20, 2023

​​A startling drop in U.S. life expectancy — and how pharma could help turn the tide

The recently observed dip was particularly acute for men, who now live an average of 5.8 fewer years than women.

By Meagan Parrish • Nov. 17, 2023

AstraZeneca showed the pandemic isn’t over for immunocompromised patients. What’s next?

Dr. Paul Moss, a hematology expert in the U.K., conducted a study with AstraZeneca showing the alarming extent to which immunocompromised patients are burdened with COVID-19.

By Michael Gibney • Nov. 16, 2023

A biotech tackles drug discovery with transcription factor know-how

Talus Bio, which developed a platform to map transcription factors, has a lead cancer candidate in the works and consults with other industry players in the complicated biology.

By Michael Gibney • Nov. 15, 2023

The power of genomics-based healthcare remains largely untapped

23andMe co-founder and CEO Anne Wojcicki discusses ways the industry could integrate genomics into healthcare.

By Alexandra Pecci • Nov. 15, 2023

6 ways to improve clinical trial diversity — as shown by J&J

Johnson & Johnson Innovative Medicine’s director of diversity, equity and inclusion in clinical trials shares key strategies for making DEI work.

By Alexandra Pecci • Nov. 14, 2023

Can Sarepta’s Duchenne gene therapy still deliver on its promise?

For Sarepta — and DMD patients — there’s a lot riding on the treatment’s next steps.

By Kelly Bilodeau • Nov. 14, 2023

Humans can’t shake the mosquito threat. Here’s what pharma has in the pipeline.

The arsenal against the world’s deadliest creature is growing and a universal vaccine is in the works.

By Kelly Bilodeau • Nov. 13, 2023

What if a CRISPR cure isn’t such an easy choice?

A gene editing therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics can mute sickle cell disease’s most damaging symptoms. Yet treatment may not be as simple as its dramatic benefit makes it seem.

By Ned Pagliarulo , Shaun Lucas • Nov. 9, 2023

23andMe CEO Anne Wojcicki’s vision for changing healthcare as a ‘full-fledged biotech’

23andMe always had bigger aims than at-home genetics testing. In this in-depth interview, the company’s founder explains its foray into pharma, drug R&D, solving cold cases and more.  

By Alexandra Pecci • Nov. 7, 2023

PharmaVoice 100s: Entrepreneurs

From biotech startups to a services agency, these entrepreneurs are hedging their bets to offer innovative approaches in patient care.

By Meagan Parrish • Nov. 3, 2023

How Big Pharma keeps the oncology engines hot with a host of strategies

From Merck and J&J to AbbVie and Eisai, the oncology field has stayed consistently devoted to churning out important therapies.

By Michael Gibney • Nov. 2, 2023

Tools like ChatGPT can personalize clinical trials tech — if companies avoid the pitfalls

From hallucinations to data privacy, pharma looks to iron out the kinks of generative AI.

By Kelly Bilodeau • Nov. 1, 2023

Roivant’s $7B Roche deal was a ‘moment of opportunity,’ CEO says

Roivant Sciences CEO Matt Gline and Telavant CEO Frank Torti know Roivant’s position as buyers and sellers in the pharma industry, and they’re embracing those opportunities.

By Michael Gibney • Oct. 31, 2023

Red Jacket: Dr. Mark Goldberg, a clinical innovator

Dr. Mark Goldberg has continually been at the cutting edge of technologies and ideas, including now as chairman and CEO of Allucent.

By Alexandra Pecci • Oct. 27, 2023

Red Jacket: Ken Getz, a champion of clinical trials

Ken Getz has spent his career improving clinical research for the benefit of patients, the life sciences industry and other R&D stakeholders.

By Alexandra Pecci • Oct. 27, 2023

The 2023 Red Jacket honorees

This year's inductees to the PharmaVoice 100 "hall of fame" are leaders who have been at the forefront — and will stay at the forefront — of industry change.

By Meagan Parrish • Oct. 27, 2023

Red Jacket: Helen Sabzevari, an immunotherapy pioneer

Precigen’s CEO is pushing for her next therapeutic breakthrough with innovative cell and gene therapy platforms.

By Meagan Parrish • Oct. 27, 2023

Cidara’s J&J-partnered immunotherapy could target flu and cancer

On a roll with promising data, the commercial-stage biotech is leveraging drug-Fc conjugates to aim a new weapon at viral targets.

By Alexandra Pecci • Oct. 26, 2023

Patient groups have become a powerhouse in R&D. Here’s a look at their impact.

“They have the money,” and they’re using it to influence drug development, according to the executive director of the IQVIA Institute for Human Data Science.

By Kelly Bilodeau • Oct. 25, 2023

An ‘inverse vaccine’ takes aim at autoimmune diseases

Backed by Pfizer, Anokion’s innovative approach to treating celiac, MS and more is showing early promise where others failed.

By Kelly Bilodeau • Oct. 23, 2023

PharmaVoice 100s: Clinical trial gurus

Industry leaders adopting cutting-edge technologies and strategies to change the paradigm of clinical research.

By Meagan Parrish • Oct. 19, 2023